| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
The primary target of Mtb-IN-2 is Mycobacterium tuberculosis. The compound affects methionine metabolism in Mtb. Mtb-IN-2 does not directly affect folate pathways. By interfering with methionine metabolism, the compound disrupts essential bacterial processes. Mtb-IN-2 distinguishes between drug-sensitive and drug-resistant Mtb H37Rv strains.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Mtb-IN-2 is a non-cytotoxic antibacterial agent against Mtb. The compound shows antimicrobial activity against both drug-sensitive and drug-resistant Mtb H37Rv strains. Mtb-IN-2 affects methionine metabolism but not folate pathways. Specific IC₅₀ or MIC values have been reported in the literature.
|
| ln Vivo |
In vivo studies have shown that Mtb-IN-2 significantly reduces colony-forming units (CFU) in the spleen of mouse tuberculosis models. The compound demonstrates significant efficacy in murine tuberculosis models. Mtb-IN-2 provides utility against both drug-sensitive and drug-resistant Mtb strains.
|
| Enzyme Assay |
For antimicrobial activity screening, standard broth microdilution methods are used. M. tuberculosis cells are cultured in appropriate media and exposed to serial dilutions of Mtb-IN-2. MIC values are determined. For mechanism studies, methionine metabolism and other pathways are analyzed.
|
| Cell Assay |
For in vitro cell-based studies, M. tuberculosis cells are cultured in appropriate media and treated with serial dilutions of Mtb-IN-2. Bacterial growth is assessed. Cytotoxicity against mammalian cells is assessed in parallel. The compound's effects on methionine metabolism are analyzed.
|
| Animal Protocol |
In vivo animal studies for Mtb-IN-2 have been conducted in mouse models of tuberculosis. Mice are infected with M. tuberculosis and treated with Mtb-IN-2. CFU in the spleen is measured. Efficacy endpoints include reduction in bacterial burden.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Mtb-IN-2 have not been comprehensively characterized. As a small molecule with a molecular weight of 308.29 g/mol, it is expected to have reasonable membrane permeability. The compound is typically stored as a powder at -20°C. Specific PK parameters such as half-life and bioavailability have not been reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for Mtb-IN-2 indicate that the compound is non-cytotoxic. Mtb-IN-2 has low toxicity. Cytotoxicity against mammalian cell lines has been assessed. The compound is for research use only and is not intended for human therapeutic use.
|
| References |
[1]. Nawrot DE, et al. Antimycobacterial pyridine carboxamides: From design to in vivo activity. Eur J Med Chem. 2023 Oct 5;258:115617.
|
| Additional Infomation |
Mtb-IN-2 is a research compound for studying tuberculosis. It is a non-cytotoxic antibacterial agent against M. tuberculosis. The compound interferes with methionine metabolism. No clinical trials or regulatory approvals have been reported. Mtb-IN-2 serves as a research tool for studying tuberculosis and developing new antitubercular agents.
|
| Exact Mass |
308.08
|
|---|---|
| Elemental Analysis |
C, 66.23; H, 3.92; N, 9.09; O, 20.76
|
| CAS # |
2861190-30-7
|
| PubChem CID |
168459170
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
456
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C=CC(=N2)C(=O)NC3=CC(=C(C=C3)C(=O)O)O
|
| InChi Key |
WOVBYNARRLCBNS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H12N2O4/c20-15-9-11(6-7-12(15)17(22)23)18-16(21)14-8-5-10-3-1-2-4-13(10)19-14/h1-9,20H,(H,18,21)(H,22,23)
|
| Chemical Name |
2-hydroxy-4-(quinoline-2-carboxamido)benzoic acid
|
| Synonyms |
Mtb-IN 2; Mtb IN-2; Mtb IN 2; Compound 10c
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
